Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 | P26358 | 2/20 | 0.73 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.73 |
| ▸ | POLB | P06746 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | GMNN | O75496 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | THPO | P40225 | 1/20 | 0.47 |
| ▸ | MTOR | P42345 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | HBB | P68871 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
| ▸ | NT5E | P21589 | 1/20 | 0.45 |
| ▸ | PNP | P00491 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19470027 | 0.90 | DNMT1 (0.69) | DNMT1ADRB1POLBLMNATP53 | |
| SCHEMBL16366026 | 0.90 | DNMT1 (0.74) | DNMT1ADRB1POLBLMNATP53 | |
| SCHEMBL10064225 | 0.90 | DNMT1 (0.74) | DNMT1ADRB1POLBLMNATP53 | |
| SCHEMBL23358428 | 0.89 | DNMT1 (0.67) | DNMT1ADRB1POLBLMNATP53 | |
| SCHEMBL20651314 | 0.89 | DNMT1 (0.67) | DNMT1ADRB1POLBLMNATP53 | |
| SCHEMBL24512397 | 0.89 | DNMT1 (0.67) | DNMT1ADRB1POLBLMNATP53 | |
| SCHEMBL23371822 | 0.89 | DNMT1 (0.67) | DNMT1ADRB1POLBLMNATP53 | |
| SCHEMBL19283452 | 0.88 | DNMT1 (0.76) | DNMT1ADRB1POLBLMNATP53 | |
| SCHEMBL23152666 | 0.87 | DNMT1 (0.65) | DNMT1ADRB1POLBLMNATP53 | |
| SCHEMBL20296324 | 0.87 | DNMT1 (0.65) | DNMT1ADRB1POLBLMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3543249-A1 | SUGAR MOIETY SILYL ETHER DERIVATIVE OF 5-AZACYTIDINE | Ohara Pharmaceutical Co., Ltd. (JP) | 2019-09-25 | — | — | EP | disclosed |
| EP-3252067-B1 | SUGAR MOIETY SILYL ETHER DERIVATIVE OF 5-AZACYTIDINE | OHARA PHARMACEUTICAL CO LTD (JP) | 2019-05-29 | — | — | EP | disclosed |
| US-10227374-B2 | Silyl etherified derivatives of 5-azacytidines in carbohydrate moiety | OHARA PHARMACEUTICAL CO., LTD. (JP) | 2019-03-12 | — | — | US | disclosed |
| US-20180179246-A1 | SILYL ETHERIFIED DERIVATIVES OF 5-AZACYTIDINES IN CARBOHYDRATE MOIETY | OHARA PHARMACEUTICAL CO., LTD. (JP) | 2018-06-28 | — | — | US | disclosed |
| US-9901641-B2 | Silyl etherified derivatives of 5-azacytidines in carbohydrate moiety | OHARA PHARMACEUTICAL CO., LTD. (JP) | 2018-02-27 | — | — | US | disclosed |
| EP-3252067-A1 | SUGAR MOIETY SILYL ETHER DERIVATIVE OF 5-AZACYTIDINE | Ohara Pharmaceutical Co., Ltd. (JP) | 2017-12-06 | — | — | EP | disclosed |
| US-20170304337-A1 | SILYL ETHERIFIED DERIVATIVES OF 5-AZACYTIDINES IN CARBOHYDRATE MOIETY | OHARA PHARMACEUTICAL CO., LTD. (JP) | 2017-10-26 | — | — | US | disclosed |
| US-9480698-B2 | Oligonucleotide analogues incorporating 5-aza-cytosine therein | ASTEX PHARMACEUTICALS, INC. (US) | 2016-11-01 | — | — | US | disclosed |
| EP-1943264-A2 | OLIGONUCLEOTIDE ANALOGUES INCORPORATING 5-AZA-CYTOSINE THEREIN | SuperGen, Inc. (US) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007041071-A2 | OLIGONUCLEOTIDE ANALOGUES INCORPORATING 5-AZA-CYTOSINE THEREIN | SUPERGEN, INC. (US) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170304337-A1 | SILYL ETHERIFIED DERIVATIVES OF 5-AZACYTIDINES IN CARBOHYDRATE MOIETY | PRMT3, RNASEL, SRM | DNMT1 65/4885ADRB1 3769/4885POLB 3765/4885 |
| US-10227374-B2 | Silyl etherified derivatives of 5-azacytidines in carbohydrate moiety | PRMT3, RNASEL, SRM | DNMT1 62/4885ADRB1 3739/4885POLB 3799/4885 |
| US-20180179246-A1 | SILYL ETHERIFIED DERIVATIVES OF 5-AZACYTIDINES IN CARBOHYDRATE MOIETY | PRMT3, RNASEL, SRM | DNMT1 62/4885ADRB1 3739/4885POLB 3799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.